The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC) has come more than two months ahead of ...

Lumakras was approved in May by the FDA as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC), becoming the first drug against a target that was long considered ...

HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster ...